Methods, kits, and devices for diagnosing, prognosing, and treating psychiatric disorders in a patient
AssigneeNorthwestern University
InventorsJiang Li, Herbert Y. Meltzer
Life of this patent
Estimating the term…
Abstract
Disclosed are methods, kits, and devices for diagnosing and treating psychiatric disorders and the symptoms thereof. The methods, kits, and devices relate to identifying genetic markers that may be utilized to diagnose and/or prognose a patient and treat the diagnosed and/or prognosed patient by administering a drug the patient based on the genetic marker having been identified. Genetic markers identified in the methods may include HTR2C polymorphisms such as a polymorphism resulting in a Cys23Ser amino acid substitution, an rs3813929 (-759C/T) polymorphism, and an rs518147 (-697G/C) polymorphism).
Claims17
A method comprising:
- (a) receiving results of a test indicating that a patient has a HTR2C polymorphism, wherein the HTR2C polymorphism is selected from the group consisting of a polymorphism resulting in a Cys23Ser amino acid substitution, an rs3813929 (-759C/T) polymorphism, and an rs518147 (-697G/C) polymorphism;
- and
- (b) administering an antipsychotic drug (APD) to the patient after receiving the results of the test.
A kit comprising:
- (a) a nucleic acid reagent that hybridizes specifically to a polymorphism in the HTR2C gene, the polymorphism selected from the group consisting of a polymorphism resulting in a Cys23Ser amino acid substitution, an rs3813929 (-759C/T) polymorphism, and an rs518147 (-697G/C) polymorphism;
- and
- (b) an antipsychotic drug (APD).
A system comprising:
- (a) a device comprising a nucleic acid reagent that hybridizes specifically to a polymorphism in the HTR2C gene, the polymorphism selected from the group consisting of a polymorphism resulting in a Cys23Ser amino acid substitution, an rs3813929 (-759C/T) polymorphism, and an rs518147 (-697G/C) polymorphism;
- and
- (b) an antipsychotic drug (APD).
Dependencies are inferred from the claim text.